Basic And Clinical Research On Renal Cell Carcinoma

Advanced Renal Cell Carcinoma (RCC) cannot be cured by surgery alone. Its resillience to irradiation and chemotherapy demands a new approach to the management of this disease. This book provides an overview of the scientific and clinical developments of RCC, and clarifies the fields ofimmunotherapy and immunobiology. The book contains a compilation of approaches that will enhance the effectiveness of the management of advancedRCC, even in the absence of definitive pre-clinical data. These require additional study and will stimulate the reassessment of preliminary results.Furthermore, preliminary results of already implemented clinical trials withbiological modifiers are presented. Of special interest are the current achievements in the field of immunotherapy using topically and subcutaneously low dosage combinations of cytokines. This concise volume will benefit those seeking a thorough review of the research and the clinical aspects of RCC simultaneously.

Advanced Renal Cell Carcinoma (RCC) cannot be cured by surgery alone. Its resillience to irradiation and chemotherapy demands a new approach to the management of this disease. This book provides an overview of the scientific and clinical developments of RCC, and clarifies the fields ofimmunotherapy and immunobiology. The book contains a compilation of approaches that will enhance the effectiveness of the management of advancedRCC, even in the absence of definitive pre-clinical data. These require additional study and will stimulate the reassessment of preliminary results.Furthermore, preliminary results of already implemented clinical trials withbiological modifiers are presented. Of special interest are the current achievements in the field of immunotherapy using topically and subcutaneously low dosage combinations of cytokines. This concise volume will benefit those seeking a thorough review of the research and the clinical aspects of RCC simultaneously.

The management of advanced renal cell carcinoma is still problematic. Surgery, although the therapy of choice for locally advanced renal tumors, is still controversial as the treatment for metastases. The role of surgery in the management of patients with pulmonary, bony, and liver metastasis is one of the subject matters discussed in this book. Our results with series of patients undergoing resection of metastases from the lung, bone, and liver show that surgery may be appropriate in selected patients with a good performance status, although most of them certainly cannot be cured by this procedure alone, i.e., in the absence of effective adjuvant therapies. As recent developments show, new strategies for immunotherapy of renal cell carcinoma represent a modest advance over traditional approaches in the treatment of this cancer, such as chemo- and radiotherapy. Clinical trials employing recombinant interferon-a and interleukin 2 produced response rates in up to 30% of patients treated, as evidenced by the European Immunotherapy Trials Program. The adverse reactions and the lack of efficacy in the majority of patients warrants the search for new immunotherapeutic approaches.

The management of advanced renal cell carcinoma is still problematic. Surgery, although the therapy of choice for locally advanced renal tumors, is still controversial as the treatment for metastases. The role of surgery in the management of patients with pulmonary, bony, and liver metastasis is one of the subject matters discussed in this book. Our results with series of patients undergoing resection of metastases from the lung, bone, and liver show that surgery may be appropriate in selected patients with a good performance status, although most of them certainly cannot be cured by this procedure alone, i.e., in the absence of effective adjuvant therapies. As recent developments show, new strategies for immunotherapy of renal cell carcinoma represent a modest advance over traditional approaches in the treatment of this cancer, such as chemo- and radiotherapy. Clinical trials employing recombinant interferon-a and interleukin 2 produced response rates in up to 30% of patients treated, as evidenced by the European Immunotherapy Trials Program. The adverse reactions and the lack of efficacy in the majority of patients warrants the search for new immunotherapeutic approaches.

Cancer is above all a heritable disorder of somatic cells and gene expression, but environment is also involved in its origin. Hereditary kidney cancer should prove valuable to understand the mechanisms of disease and to the development of therapeutic measures. Recently, scientists have succeeded in cloning and identifying the genes responsible for the following familial kidney cancers: von Hippel-Lindau disease, papillary renal cell carcinoma, tuberous sclerosis and Wilms tumor (all autosomal dominant). This book brings together some of the most recent advances made with respect to kidney cancers: Leading investigators present recent results on VHL, MET, TSC1 and TSC2 and WT1 genes, among others, as well as on environmentally induced kidney cancers (caused by long-term hemodialysis or induced chemically) and their treatments (surgery and gene therapy), providing an excellent survey of this field. This publication will be of interest to both researchers and clinicians concerned with cancer of the kidney.

Cancer is above all a heritable disorder of somatic cells and gene expression, but environment is also involved in its origin. Hereditary kidney cancer should prove valuable to understand the mechanisms of disease and to the development of therapeutic measures. Recently, scientists have succeeded in cloning and identifying the genes responsible for the following familial kidney cancers: von Hippel-Lindau disease, papillary renal cell carcinoma, tuberous sclerosis and Wilms tumor (all autosomal dominant). This book brings together some of the most recent advances made with respect to kidney cancers: Leading investigators present recent results on VHL, MET, TSC1 and TSC2 and WT1 genes, among others, as well as on environmentally induced kidney cancers (caused by long-term hemodialysis or induced chemically) and their treatments (surgery and gene therapy), providing an excellent survey of this field. This publication will be of interest to both researchers and clinicians concerned with cancer of the kidney.

​​ ​The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.​